Utku Dönem Gündoğdu

The Clinical Effect of Triglyceride Glucose Index, an Insulin Resistance Marker, in Predicting Neuropathy Induced by the FOLFOX Chemotherapy Protocol

Utku Dönem Gündoğdu, Funda Karabağ & Fuzuli Tuğrul · Journal of Advances in Medicine and Medical Research · 2022

Objective: FOLFOX chemotherapy protocol is a chemotherapeutic agent used in both adjuvant and neoadjuvant chemotherapy of many malignancies such as colon, rectum, stomach, gallbladder, and pancreatic cancer. Despite its therapeutic efficacy, neuropathy is the most dose-limiting f...

Open access Research Article 10.9734/jammr/2022/v34i2231575

Atherogenic Plasma Index Levels of Colon Cancer Patients after Chemotherapy

Utku Dönem Gündoğdu & Funda Karabağ Çoban · Journal of Pharmaceutical Research International · 2021

Objectives: Despite newly developed treatment modalities, colorectal cancer is still the leading cause of cancer deaths. In recent years, studies have been carried out to suggest that lipid metabolism may play a role in cancer development and metastasis. Methods: Lipid metabolism...

Open access Research Article 10.9734/jpri/2021/v33i59B34374

A Study of Atherogenic Plasma & Triglyceride-Glucose Indices and Monocyte/HDL-C Ratios in Colon Cancer Patients

Utku Dönem Gündoğdu & Funda Karabağ Çoban · Journal of Pharmaceutical Research International · 2021

Colon cancer is a tumor of the large intestine. It is the third most common cause of cancer-related death in the United States. However, most people with colon cancer get better if the cancer is found early. The atherogenic index of plasma (AIP), triglyceride-glucose (TyG) index,...

Open access Research Article 10.9734/jpri/2021/v33i46B32935